Glenmark Pharma Q4 net profit up 6 percent at Rs 233 point 87 crore

Glenmark Pharma

Glenmark Pharma

Pharmaceutical company Glenmark Pharmaceuticals reported a consolidated net profit of Rs 233.87 crore for the last quarter ended March 31, 2021, a growth of six per cent.

New Delhi. Pharmaceutical company Glenmark Pharmaceuticals reported a consolidated net profit of Rs 233.87 crore for the last quarter ended March 31, 2021, a growth of six per cent. The company earned this profit with the help of better sales. In the same quarter of the year 2019-20, it had a net profit of Rs 220.30 crore. The company said in a regulatory notice on Friday that it earned a revenue of Rs 2,859.9 crore from business in the March 2021 quarter as compared to Rs 2,767.5 crore in March 2020.

The company earned a total net profit of Rs 970.1 crore in the entire financial year 2020-21. In the financial year 2019-20 it was Rs 776 crore. In the financial year 2020-21, the company earned a total revenue of Rs 10,943.9 crore, which was Rs 10.641 crore in the financial year 2019-20.

Glenn Saldanha, Chairman and Managing Director, Glenmark said, “We have had a steady performance this year despite the business challenges posed by Kovid-19. We led the fight against COVID-19 in India as soon as it started with our top brand Fabiflu.

The board of the company has recommended a dividend of Rs 2.50 per share for the financial year 2020-21.




Leave a Reply

Your email address will not be published. Required fields are marked *